ABOUT US

We provide innovative gene editing reagents and screening services for the global R&D market. Our success is based on the proprietary 3Cs technology developed at Goethe University’s Institute of Biochemistry II (IBC2). 

Vivlion is a spin-out of Goethe University Frankfurt am Main founded in December 2018 by a team of scientists together with Goethe University Frankfurt am Main as a shareholder. Seed funding was secured by a private equity company, gsccb Beteiligungsverwaltung GmbH.

Ivan Đikić
CEO
Manuel Kaulich
CSO

Internationally renowned biomedical scientist and professor of Goethe University Frankfurt am Main.

Lead inventor of 3Cs technology and group leader of Goethe University Frankfurt am Main.

Kerstin Koch
COO

Experienced project manager with strong background in life sciences and journalism.

Vivlion is advised by representatives of Goethe University Frankfurt am Main, its technology transfer company Innovectis GmbH and of gsccb Beteiligungsverwaltung GmbH.

cropped-logo_innovectis_1-2.png
Goethe-Logo 4c.png
Logo_IBCII_cmyk.png

© 2019 by Vivlion GmbH                                                                                                                           
Geschäftsführer: Prof. Dr. Ivan Dikic • Dr. Manuel Kaulich • Dr. Kerstin Koch            
IMPRINT    PRIVACY    T&C

CRISPR gRNA library libraries 3Cs CRISPR/Cas Vivlion GmbH pooled arrayed CRISPR/Cas reagents screens validated products single multiplex multiplexing fixed-pair predefined combinations combinatorial screening